To obtain a grasp of current methods in the management of lower urinary tract symptoms (LUTS) in the context of benign prostatic hyperplasia (BPH). Including pharmaceutical therapy as well as new less invasive alternatives, as well as peri-procedural considerations, anticipated results, and value-based considerations. The most widely used intervention for LUTS associated with BPH is medical treatment, particularly alpha blockers (ABs) and 5-alpha reductase inhibitors (5-ARI). Several minimally invasive surgical therapies (MISTs) have evolved that give effective and long-lasting benefits while generally avoiding the sexual side effects of more invasive surgical alternatives. The implementation of value-based health care has resulted in more cost-conscious medical care and is set to impact the landscape of LUTS related with BPH therapy.
A paradigm change in management is predicted as population-based and social requirements continue to impact medical care for males with LUTS associated with BPH.